Research Analysts Set Expectations for Brainsway Q1 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Equities research analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for Brainsway in a research report issued on Thursday, March 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.06 per share for the quarter, up from their prior forecast of $0.05. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Brainsway’s Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.42 EPS.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. The company had revenue of $14.55 million during the quarter, compared to the consensus estimate of $14.02 million. Brainsway had a return on equity of 11.10% and a net margin of 14.62%.

Other research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Northland Securities set a $15.00 target price on shares of Brainsway in a report on Thursday, January 22nd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Brainsway in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Brainsway Stock Down 0.4%

Shares of NASDAQ BWAY opened at $13.65 on Monday. The firm’s 50-day moving average price is $12.19 and its 200-day moving average price is $9.59. Brainsway has a 52-week low of $3.92 and a 52-week high of $14.65. The company has a market cap of $535.35 million, a PE ratio of 54.60 and a beta of 1.20.

Institutional Investors Weigh In On Brainsway

A number of large investors have recently made changes to their positions in BWAY. ARK Investment Management LLC bought a new position in shares of Brainsway in the 4th quarter worth approximately $2,422,000. Y.D. More Investments Ltd boosted its holdings in shares of Brainsway by 559.8% in the fourth quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock worth $2,187,000 after buying an additional 97,537 shares during the last quarter. UBS Group AG grew its position in Brainsway by 2,028.6% during the third quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after buying an additional 60,877 shares during the period. Two Sigma Investments LP grew its position in Brainsway by 25.2% during the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock valued at $1,551,000 after buying an additional 20,706 shares during the period. Finally, Millennium Management LLC increased its holdings in Brainsway by 69.6% during the third quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock valued at $600,000 after buying an additional 16,354 shares during the last quarter. 30.11% of the stock is currently owned by institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.